J.L. Lee

1.2k total citations
15 papers, 472 citations indexed

About

J.L. Lee is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, J.L. Lee has authored 15 papers receiving a total of 472 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 5 papers in Surgery. Recurrent topics in J.L. Lee's work include Renal cell carcinoma treatment (7 papers), Renal and related cancers (5 papers) and Bladder and Urothelial Cancer Treatments (4 papers). J.L. Lee is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Renal and related cancers (5 papers) and Bladder and Urothelial Cancer Treatments (4 papers). J.L. Lee collaborates with scholars based in South Korea, United States and Canada. J.L. Lee's co-authors include Yoon‐Koo Kang, Jane Koh, Kyung Chul Moon, Jin-Hyuk Choi, Hanjong Ahn, Daniel Lee, Cheryn Song, Jun Hyuk Hong, Inkeun Park and Bumsik Hong and has published in prestigious journals such as Annals of Oncology, British Journal of Dermatology and European Journal of Surgical Oncology.

In The Last Decade

J.L. Lee

15 papers receiving 462 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J.L. Lee South Korea	7	294	179	139	139	94	15	472
Ewa Chmielowska Poland	12	251 0.9×	132 0.7×	109 0.8×	119 0.9×	40 0.4×	44	468
M.C. Cox United States	10	180 0.6×	177 1.0×	91 0.7×	117 0.8×	106 1.1×	23	429
Shridevi Karikehalli United States	3	144 0.5×	150 0.8×	113 0.8×	92 0.7×	36 0.4×	5	423
Erjiang Tang China	10	177 0.6×	117 0.7×	58 0.4×	148 1.1×	38 0.4×	22	368
Andrew W. Pippas United States	7	636 2.2×	319 1.8×	79 0.6×	124 0.9×	38 0.4×	10	727
Öznur Bal Türkiye	12	175 0.6×	142 0.8×	78 0.6×	76 0.5×	37 0.4×	49	380
Nicolas Moosmann Germany	12	449 1.5×	216 1.2×	45 0.3×	89 0.6×	27 0.3×	39	512
Shuji Arita Japan	15	302 1.0×	161 0.9×	218 1.6×	46 0.3×	17 0.2×	44	558
B. Massuti Sureda Spain	5	263 0.9×	125 0.7×	50 0.4×	47 0.3×	57 0.6×	26	350

Countries citing papers authored by J.L. Lee

Since Specialization

Citations

This map shows the geographic impact of J.L. Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.L. Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.L. Lee more than expected).

Fields of papers citing papers by J.L. Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.L. Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.L. Lee. The network helps show where J.L. Lee may publish in the future.

Co-authorship network of co-authors of J.L. Lee

This figure shows the co-authorship network connecting the top 25 collaborators of J.L. Lee. A scholar is included among the top collaborators of J.L. Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.L. Lee. J.L. Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Kim, Dae Sung, et al.. (2024). Factors Affecting Adherence to National Colorectal Cancer Screening: A 12-Year Longitudinal Study Using Multi-Institutional Pooled Data in Korea. Journal of Korean Medical Science. 39(4). e36–e36. 1 indexed citations

Lee, J.L., et al.. (2024). Evaluation of PD-L1 expression in PBRM1-altered clear cell renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 42(12). 454.e21–454.e30. 1 indexed citations

Rosenberg, Jonathan E., Thomas Powles, Guru Sonpavde, et al.. (2021). 698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma. Annals of Oncology. 32. S710–S711. 2 indexed citations

Choueiri, Toni K., Piotr Tomczak, S.H. Park, et al.. (2021). 653O Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564. Annals of Oncology. 32. S679–S680. 1 indexed citations

Motzer, Robert J., Konstantin Penkov, John B.A.G. Haanen, et al.. (2018). JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Annals of Oncology. 29. viii724–viii724. 24 indexed citations

Bellmunt, Joaquim, Ronald de Wit, David J. Vaughn, et al.. (2018). Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045. Annals of Oncology. 29. viii320–viii321. 2 indexed citations

Donskov, Frede, David F. McDermott, J.L. Lee, et al.. (2018). KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC). Annals of Oncology. 29. viii307–viii307. 21 indexed citations

Gross‐Goupil, Marine, Tae Gyun Kwon, Masatoshi Eto, et al.. (2018). Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results. Annals of Oncology. 29. viii303–viii303. 10 indexed citations

Sonpavde, Guru, Gregory R. Pond, Giuseppe Di Lorenzo, et al.. (2016). Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. 14(6). 494–498. 1 indexed citations

10.

Lee, J.L., Inkeun Park, Daniel Lee, et al.. (2015). RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Annals of Oncology. 26(11). 2300–2305. 86 indexed citations

11.

Sun, Yinghao, Hongcheng Shi, Chi‐Hau Chen, et al.. (2015). 243PD Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets). Annals of Oncology. 26. ix71–ix71. 1 indexed citations

12.

Han, Sungpil, Seunghyun Bang, T.W. Kim, et al.. (2009). Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines. British Journal of Dermatology. 162(2). 371–379. 19 indexed citations

13.

Lee, J.L., et al.. (2009). Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. British Journal of Dermatology. 161(5). 1045–1051. 172 indexed citations

14.

Kim, T.M., Yoon Kyung Jeon, Young Seon Hong, et al.. (2008). Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Annals of Oncology. 19(8). 1477–1484. 125 indexed citations

15.

Koo, Dong‐Hoe, J.L. Lee, T.W. Kim, et al.. (2007). Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma. European Journal of Surgical Oncology. 33(7). 843–848. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact